We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Review Promotes Use of Clinical Exome Sequencing for Diagnosis of Neurological Diseases

By LabMedica International staff writers
Posted on 18 Apr 2016
Print article
A recent review discussed the potential role of clinical exome sequencing for diagnosis of neurological diseases, focusing on the benefits to patients, limitations of the technique, appropriate use, and costs.

Investigators at the University of California, Los Angeles wished to improve the current situation in which the state-of-the-art molecular genetic test that provides an unbiased analysis of all protein-coding sequences in the roughly 21,000 genes in the human genome is rarely used for the diagnosis of neurological disorders.

The human exome is critical to our genetic make-up and is generally accepted as having the greatest influence on how the genetic blueprint is utilized. The exome is defined as all coding exons in the genome and is comprised of the most functionally relevant and best understood 1% of the human genome. Targeted sequencing is a powerful technique allowing researchers to focus their analysis on this critical portion of the genome.

A pertinent example of the technique's potential reported in 2014 showed that 20% of a group of individuals with spinocerebellar ataxia could be diagnosed immediately using exome sequencing, and that useful genetic information could be obtained in more than 60% of the subjects, regardless of their age at onset of the disease or their family history.

“Despite extensive literature supporting the use of this technology, many insurance companies still consider it to be investigational and may refuse coverage,” said first author Dr. Brent Fogel, assistant professor of neurology and human genetics at the University of California, Los Angeles. “Our article outlines the appropriate use, benefits and limitations of exome sequencing that these companies need to consider when making coverage decisions.”

The review was published in the April 2016 issue of the journal Neurology Clinical Practice.


Related Links:

University of California, Los Angeles


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.